Get started
Author

Andreas Kapatais

Observed names: A. Kapatais, ANDREAS Kapatais
ORCID: 0000-0002-6294-7481
Observed ORCID: 0000-0002-6294-7481
OpenAlex ID: A5014748521
High levels of all-cause mortality among people who inject drugs from 2018 to 2022
2024 · Sotirios Roussos, Theodoros Angelopoulos, et al. · International Journal of Drug Policy · 12
PDF
HERACLIS‐HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg ‐positive patients
2023 · George Papatheodoridis, Konstantinos Mimidis, et al. · Liver International · 11
PDF
HERACLIS‐TAF : a multi‐centre prospective cohort study on 2‐year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks
2022 · George V. Papatheodoridis, Kostas Mimidis, et al. · Alimentary Pharmacology & Therapeutics · 10
Incidence of primary hepatitis C infection among people who inject drugs during 2012–2020 in Athens, Greece
2024 · Sotirios Roussos, Christos Bagos, et al. · Journal of Viral Hepatitis · 5
Microvesicle Profiles in Patients with HIV, HBV, and HCV Infections: An Exploratory Pilot Study
2026 · Georgios Dryllis, Sotirios P. Fortis, et al. · Microorganisms · 1
PDF
Case control study for the effect of functional food consumption on biomarkers of patients with viral hepatopathy (Hepatitis B and C) and metabolic syndrome
2022 · Theofani Karaoulani, Christelos Kapatais, et al. · Functional Food Science · 1
PDF
Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF)
2020 · George Papatheodoridis, Konstantinos Mimidis, et al. · Journal of Hepatology · 1
PDF
Factors associated with failure to link people who inject drugs to HCV care and treatment: results from a community-based seek-test-treat program in Athens, Greece (ARISTOTLE HCV-HIV)
2020 · Vana Sypsa, George Kalamitsis, et al. · Journal of Hepatology · 1
PDF
Predictors of Sustained Virological Response (SVR) in Patients with Advanced Chronic Hepatitis C (CHC) Treated with Current Direct Acting Antiviral(s) (DAA). Heraclis: Hellenic Multicenter Real-Life Cohort Study
2017 · George Papatheodoridis, Spilios Manolakopoulos, et al. · Gastroenterology · 1
Increasing HCV Diagnosis and Treatment Uptake Among Community‐Recruited People Who Inject Drugs in Athens, Greece, During the Transition to Unrestricted Access to Direct‐Acting Antivirals
2026 · Sotirios Roussos, Georgios Papatheodoridis, et al. · Journal of Viral Hepatitis
Externally Validated Probabilistic Modeling of a Predefined Entecavir Resistance Pathway in HBV Using Independent Public Repositories
2026 · Christelos Kapatais, Fanie Karaoulani, et al. · Viruses
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)
2023 · George Papatheodoridis, Spilios Manolakopoulos, et al. · Journal of Hepatology
Two-year safety and efficacy of tenofovir alafenamide in chronic hepatitis B: a HEllenic multicenter ReAl-life CLInical Study (HERACLIS-TAF)
2022 · George Papatheodoridis, Konstantinos Mimidis, et al. · Journal of Hepatology
Loss of HbsAg is enough to discontinue long-term therapy with Nucleos(T)ide analogues in HbeAg negative CHB patients in real clinical practice?
2018 · A. Kapatais, P. Labropoulos, et al. · Journal of Hepatology
Platelets represent an independent predictor of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral(s) (DAA). HERACLIS: Hellenic multicenter real-life cohort study
2017 · G. Papatheodoridis, A. Kapatais, et al. · Journal of Hepatology
Works count: 15
Citation count: 43
H-index: 4
I10-index: 3
Year
Topic
Type